サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1781969

拘束性ペプチド医薬品の世界市場：ペプチドの種類別・治療領域別・合成方法別・投与経路別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Constrained Peptide Drugs Market, By Peptide Type, By Therapeutic Area, By Synthesis Method, By Route of Administration, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 316 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.67円
拘束性ペプチド医薬品の世界市場：ペプチドの種類別・治療領域別・合成方法別・投与経路別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年06月04日
発行: AnalystView Market Insights
ページ情報: 英文 316 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートのハイライト

拘束性ペプチド医薬品の市場規模は2024年に15億6,032万米ドルとなり、2025年から2032年にかけて16.20%のCAGRで拡大

拘束性ペプチド医薬品の市場力学

慢性疾患有病率の増加が市場需要を促進

慢性疾患の有病率の上昇が、世界の拘束性ペプチド医薬品市場の成長を促進しています。CDCによると、米国では成人の約10人に6人が慢性疾患を患っており、拘束性ペプチド医薬品のような標的治療薬の需要を促進しています。そのほか、ペプチド安定化の進歩も市場成長を押し上げる要因のひとつと予測されています。しかし、高い製造コストと規制上の課題が、今後数年間の市場成長の妨げになると予想されます。それとは逆に、腫瘍学における用途の拡大と個別化投資の増加は、個々の患者のプロファイルに合わせて設計されたペプチド医薬品の機会を提供しています。

拘束性ペプチド医薬品市場：主な考察

制約の多いペプチド医薬品市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2025～2032年）に約16.20%のCAGRで毎年成長すると推定されます。

ペプチドの種類別では、環状ペプチドが2024年に最大の市場シェアを示すと予測されました。

治療領域別では、2024年には腫瘍領域が主要治療領域となります。

合成方法別では、固相ペプチド合成が2024年の主要合成方法でした。

投与経路別では、皮下投与が2024年のトップ

エンドユーザー別では、病院が2024年のトップ

地域別では、北米が2024年の売上高でトップ

拘束性ペプチド医薬品市場：セグメンテーション分析

拘束性ペプチド医薬品の世界市場は、ペプチドの種類、治療領域、合成方法、投与経路、エンドユーザー、地域に基づいてセグメント化されます。

市場はペプチドの種類に基づき、環化ペプチド、大環状ペプチド、D-ペプチド、ステープルドペプチドの4つのカテゴリーに分けられます。環化ペプチドセグメントは、他のペプチドの種類に比べて安定性が高く、バイオアベイラビリティが改善され、治療領域で広く応用されていることから、予測期間中に主要な市場シェアを占めると予想されます。

市場は、治療領域別に感染症、心血管疾患、中枢神経系疾患、腫瘍、代謝性疾患の2つに分類されます。腫瘍領域は、がん罹患率の増加とがん標的治療におけるペプチド医薬品の有効性により、世界の拘束性ペプチド医薬品市場で主要な市場シェアを占めると予想されます。

拘束性ペプチド医薬品市場：地域別分析

北米地域は、高度な医療インフラ、研究開発投資の増加、革新的な治療法の高い採用率に牽引され、予測期間中、拘束性ペプチド医薬品市場の主要シェアを占めると予測されます。一方、アジア太平洋は、医療意識の高まり、患者数の拡大、新興国でのバイオテクノロジーおよび製薬分野への投資の増加により、最も速い速度で成長すると予測されます。

拘束性ペプチド医薬品市場：競合情勢

標的を絞った安定した治療薬に対する需要の高まりが、拘束性ペプチド医薬品の技術革新を後押ししています。各社はペプチド安定化技術の進歩や送達方法の改良に注力し、有効性や患者のコンプライアンスを向上させています。研究機関との戦略的提携や共同研究は医薬品開発を加速し、製品パイプラインを拡大します。さらに、製造能力の拡大や新興市場への参入への投資は、拡大する医療ニーズに対応するのに役立ちます。個別化医療と新規ペプチド製剤の開発に重点を置くことで、進化する情勢における競合情勢はさらに強化されます。

目次

第1章 拘束性ペプチド医薬品市場の概要

  • 分析範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 拘束性ペプチド医薬品の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 拘束性ペプチド医薬品市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 拘束性ペプチド医薬品市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 拘束性ペプチド医薬品の市場情勢

  • 拘束性ペプチド医薬品の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 拘束性ペプチド医薬品市場：ペプチドの種類別

  • 概要
    • セグメント別シェア分析：ペプチドの種類別
    • 環状ペプチド
    • 大環状ペプチド
    • D-ペプチド
    • ステープルペプチド

第8章 拘束性ペプチド医薬品市場：治療領域別

  • 概要
    • セグメント別シェア分析：治療領域別
    • 感染症
    • 心血管疾患
    • 中枢神経疾患
    • 腫瘍
    • 代謝障害

第9章 拘束性ペプチド医薬品市場：合成方法別

  • 概要
    • セグメント別シェア分析：合成方法別
    • 固相ペプチド合成
    • 組み換え技術

第10章 拘束性ペプチド医薬品市場：投与経路別

  • 概要
    • セグメント別シェア分析：投与経路別
    • オーラル
    • 静脈内
    • 経皮
    • 皮下

第11章 拘束性ペプチド医薬品市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 病院
    • 研究機関
    • 製薬企業

第12章 拘束性ペプチド医薬品市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析：拘束性ペプチド医薬品業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Amgen Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sanofi SA
    • Bicycle Therapeutics PLC
    • Bristol-Myers Squibb Company
    • Aileron Therapeutics, Inc.
    • Eli Lilly and Company
    • Aileron Therapeutics Inc.
    • Spexis AG
    • Santhera Pharmaceuticals
    • Protagonist Therapeutics Inc.
    • Union Chimique Belge SA（UCB）
    • Biosynth（Pepscan）
    • Creative Peptides
    • Pepticom Ltd.
    • Bio-Synthesis Inc.
    • PeptiDream Inc.
    • CPC Scientific Inc.
    • Chugai Pharmaceutical Co. Ltd.
    • Circle Pharma
    • Others

第14章 AnalystViewの全方位的分析

目次
Product Code: ANV5366

REPORT HIGHLIGHT

Constrained peptide drugs market size was valued at US$ 1,560.32 Million in 2024, expanding at a CAGR of 16.20% from 2025 to 2032.

Constrained peptide drugs are specially designed molecules where the peptide's structure is chemically "locked" into a stable shape. This constraint improves their stability, enhances binding to specific targets, and increases resistance to degradation by enzymes in the body. These features make them highly effective in treating diseases by precisely interacting with biological molecules, offering advantages over traditional peptides such as improved potency, selectivity, and longer-lasting therapeutic effects.

Constrained Peptide Drugs Market- Market Dynamics

Increasing prevalence of chronic diseases to propel market demand

The rising prevalence of chronic diseases is driving the growth of the global constrained peptide drugs market. According to the CDC, approximately 6 in 10 adults in the U.S. have a chronic disease, driving demand for targeted therapies like constrained peptide drugs. Besides, advancements in peptide stabilization is another factor projected to boost the market growth. However, high production costs and regulatory challenges is expected to hamper the market growth in the coming years. On the contrary, expanding applications in oncology and increasing investment in personalized, providing opportunities for peptide drugs designed for individual patient profiles.

Constrained Peptide Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.20% over the forecast period (2025-2032)

Based on Peptide Type segmentation, cyclized peptides was predicted to show maximum market share in the year 2024

Based on Therapeutic Area segmentation, oncology was the leading Therapeutic Area in 2024

Based on Synthesis Method segmentation, solid phase peptide synthesis was the leading Synthesis Method in 2024

Based on Route of Administration segmentation, subcutaneous was the leading Route of Administration in 2024

Based on end user segmentation, Hospital was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Constrained Peptide Drugs Market- Segmentation Analysis:

The Global Constrained Peptide Drugs Market is segmented on the basis of Peptide Type, Therapeutic Area, Synthesis Method, Route of Administration, End User, and Region.

The market is divided into four categories based on Peptide Type: cyclized peptides, macrocyclic peptides, D-peptides, and stapled peptides. The cyclized peptides segment is expected to hold the major market share during the forecast period, driven by their enhanced stability, improved bioavailability, and widespread applications in therapeutic areas compared to other peptide types.

The market is divided into two categories based on Therapeutic Area: infectious diseases, cardiovascular diseases, Cns Disorders, oncology, and metabollic disorders. The oncology segment is expected to hold the major market share in the global constrained peptide drugs market, due to increasing cancer prevalence and the effectiveness of peptide drugs in targeted cancer therapies.

Constrained Peptide Drugs Market- Geographical Insights

The North America region is expected to hold the major constrained peptide drugs market share during the forecast period, driven by advanced healthcare infrastructure, increased R&D investments, and high adoption of innovative therapies. Meanwhile, the Asia-Pacific region is projected to grow at the fastest rate due to rising healthcare awareness, expanding patient populations, and growing investments in biotechnology and pharmaceutical sectors across emerging economies.

Constrained Peptide Drugs Market- Competitive Landscape:

Rising demand for targeted and stable therapeutics drives innovation in constrained peptide drugs. Companies focus on advancing peptide stabilization technologies and enhancing delivery methods to improve efficacy and patient compliance. Strategic partnerships and collaborations with research institutes accelerate drug development and expand product pipelines. Additionally, investments in expanding manufacturing capabilities and penetrating emerging markets help capitalize on growing healthcare needs. Emphasis on personalized medicine and novel peptide formats further strengthens competitive positioning in this evolving landscape.

Recent Developments:

In January 2025, Bicycle Therapeutics plc shared updated Phase 1 combination results for zelenectide pevedotin with pembrolizumab in cisplatin-ineligible metastatic urothelial cancer patients, along with key accomplishments and strategic plans for 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi S.A.
  • Bicycle Therapeutics PLC
  • Bristol-Myers Squibb Company
  • Aileron Therapeutics, Inc.
  • Eli Lilly and Company
  • Aileron Therapeutics Inc.
  • Spexis AG
  • Santhera Pharmaceuticals
  • Protagonist Therapeutics Inc.
  • Union Chimique Belge S.A. (UCB)
  • Biosynth (Pepscan)
  • Creative Peptides
  • Pepticom Ltd.
  • Bio-Synthesis Inc.
  • PeptiDream Inc.
  • CPC Scientific Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • Circle Pharma
  • Others

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY PEPTIDE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Cyclized Peptides
  • Macrocyclic Peptides
  • D-Peptides
  • Stapled Peptides

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Infectious Diseases
  • Cardiovascular Diseases
  • Cns Disorders
  • Oncology
  • Metabollic Disorders

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY SYNTHESIS METHOD- MARKET ANALYSIS, 2019 - 2032

  • Solid Phase Peptide Synthesis
  • Recombinant Technology

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous
  • Transdermal
  • Subcutaneous

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Research Institutes
  • Pharmaceutical Companies

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Constrained Peptide Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Constrained Peptide Drugs Market Snippet by Peptide Type
    • 2.1.2. Constrained Peptide Drugs Market Snippet by Therapeutic Area
    • 2.1.3. Constrained Peptide Drugs Market Snippet by Synthesis Method
    • 2.1.4. Constrained Peptide Drugs Market Snippet by Route of Administration
    • 2.1.5. Constrained Peptide Drugs Market Snippet by End User
    • 2.1.6. Constrained Peptide Drugs Market Snippet by Country
    • 2.1.7. Constrained Peptide Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Constrained Peptide Drugs Key Market Trends

  • 3.1. Constrained Peptide Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Constrained Peptide Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Constrained Peptide Drugs Market Opportunities
  • 3.4. Constrained Peptide Drugs Market Future Trends

4. Constrained Peptide Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Constrained Peptide Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Constrained Peptide Drugs Market Landscape

  • 6.1. Constrained Peptide Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Constrained Peptide Drugs Market - By Peptide Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Peptide Type, 2024 & 2032 (%)
    • 7.1.2. Cyclized Peptides
    • 7.1.3. Macrocyclic Peptides
    • 7.1.4. D-Peptides
    • 7.1.5. Stapled Peptides

8. Constrained Peptide Drugs Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 8.1.2. Infectious Diseases
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Cns Disorders
    • 8.1.5. Oncology
    • 8.1.6. Metabollic Disorders

9. Constrained Peptide Drugs Market - By Synthesis Method

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Synthesis Method, 2024 & 2032 (%)
    • 9.1.2. Solid Phase Peptide Synthesis
    • 9.1.3. Recombinant Technology

10. Constrained Peptide Drugs Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 10.1.2. Oral
    • 10.1.3. Intravenous
    • 10.1.4. Transdermal
    • 10.1.5. Subcutaneous

11. Constrained Peptide Drugs Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Research Institutes
    • 11.1.4. Pharmaceutical Companies

12. Constrained Peptide Drugs Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Constrained Peptide Drugs Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Constrained Peptide Drugs Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Constrained Peptide Drugs Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Constrained Peptide Drugs Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Constrained Peptide Drugs Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Constrained Peptide Drugs Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Amgen Inc.
    • 13.2.2. Pfizer Inc.
    • 13.2.3. Novartis AG
    • 13.2.4. Merck & Co., Inc.
    • 13.2.5. F. Hoffmann-La Roche Ltd.
    • 13.2.6. Sanofi S.A.
    • 13.2.7. Bicycle Therapeutics PLC
    • 13.2.8. Bristol-Myers Squibb Company
    • 13.2.9. Aileron Therapeutics, Inc.
    • 13.2.10. Eli Lilly and Company
    • 13.2.11. Aileron Therapeutics Inc.
    • 13.2.12. Spexis AG
    • 13.2.13. Santhera Pharmaceuticals
    • 13.2.14. Protagonist Therapeutics Inc.
    • 13.2.15. Union Chimique Belge S.A. (UCB)
    • 13.2.16. Biosynth (Pepscan)
    • 13.2.17. Creative Peptides
    • 13.2.18. Pepticom Ltd.
    • 13.2.19. Bio-Synthesis Inc.
    • 13.2.20. PeptiDream Inc.
    • 13.2.21. CPC Scientific Inc.
    • 13.2.22. Chugai Pharmaceutical Co. Ltd.
    • 13.2.23. Circle Pharma
    • 13.2.24. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us